Demo creative for Header leaderboard (728x90)

BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026

MCAP MediaWire
Image: MCAP MediaWire

Conference call and webcast to be held at 4:30 PM ET

POMPANO BEACH, Fla., October 29, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its third quarter 2026 financial results on Thursday, November 12, 2026, and will host a conference call and webcast at 4:30 PM ET.

BioStem Technologies (NASDAQ: BSEM) to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026

The webcast will feature an overview of the quarter from BioStem Technologies management. To register for the event, please click HERE .

Conference Call & Webcast Information:

Conference ID:  107 437 691

North America Toll-Free:  +1 833-461-5787

International Toll: +1 585-542-9983

Webcast Link: https://events.q4inc.com/attendee/107437691

About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion product lines.

Join BioStem’s Distribution List & Social Media:

To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .

Contact BioStem:

Website:  www.biostemtechnologies.com

E-Mail:  pr@biostemtech.com

X:  @BSEM_Tech

Facebook:  BioStemTechnologies

Phone: 954-380-8342

Investor Relations:

Philip Trip Taylor, Gilmartin

ir@biostemtech.com

Source: BioStem Technologies, Inc.

RSS News Feed PRISM MediaWire: https://prismmediawire.com/feed/

$BSEM BioStem Technologies (Nasdaq: BSEM) will report Q3 2026 financial results on November 12 and host a management webcast at 4:30 p.m. ET https://t.co/gHVtwYERok pic.twitter.com/1PHFweAJhJ

— PRISM MediaWire (@prism_mediawire) October 29, 2026

Follow @prism_mediawire

window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag(‘js’, new Date());

gtag(‘config’, ‘G-CFKYJ1EDBW’);

The post BioStem Technologies to Host Third Quarter 2026 Financial Results Conference Call on November 12, 2026 first appeared on PRISM MediaWire .

Demo creative for Between results (336x280)

More in Biotechnology

See all